Back

High individual variability in LDL-reductions after inclisiran administration in a "real-world setting"

26 August 2022 (16:10 - 16:20)
Organised by:
Congress Presentation Part of: Lipid-lowering by PCSK9 modulation: what’s new? Lipid-Lowering Agents ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Professor Oliver Weingaertner

University hospital Jena, Jena (Germany)

4 More presentations in this session

Presentation thumbnail
PCSK-9-inhibitor therapy improves endothelial function in high-risk patients with cardiovascular disease
Doctor D. Kannenkeril (Erlangen, DE)
Abstract Slides Video
Presentation thumbnail
Impact of alirocumab added to high-intensity statin therapy on platelet function in AMI patients: a pre-specified substudy of the randomized, placebo-controlled PACMAN-AMI trial
Doctor L. Raber (Bern, CH)
Abstract Slides Video
Presentation thumbnail
Low-density lipoprotein cholesterol reduction with evolocumab and its use in clinical practice: evidence from swedish national register data
Professor M. Svensson (Uppsala, SE)
Abstract Slides Video
Presentation thumbnail
Evolocumab treatment is associated with early and sustained reductions in low-density cholesterol (LDL-C) over 30 months: final results from the pan-European observational HEYMANS registry
Professor K. Ray (London, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Lipid-lowering by PCSK9 modulation: what’s new?

The Event

Event poster

ESC Congress 2022

26 August 2022 16:10 CET
You may be interested in
thumbnail
Congress Presentation
What have we learned? Long-term safety and efficacy of inclisiran

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources